Duan Liyun, Jin De, An Xuedong, Zhang Yuehong, Zhao Shenghui, Zhou Rongrong, Duan Yingying, Zhang Yuqing, Liu Xinmin, Lian Fengmei
Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
China Academy of Chinese Medical Sciences, Beijing 100700, China.
Evid Based Complement Alternat Med. 2021 Jul 8;2021:5577610. doi: 10.1155/2021/5577610. eCollection 2021.
(RC) showed a significant effect on PCOS, but its mechanism in PCOS remains unclear.
The components of RC were searched by TCMSP. The Smiles number of the active ingredients was queried through PubChem, and the predicted targets were obtained from the SwissTargetPrediction database. The DrugBank, GeneCards, and DisGeNET databases were retrieved to acquire the related targets of PCOS. Then, the network of compound-target was constructed. The core targets were analyzed using protein-protein interaction (PPI) analysis, and the binding activities were verified by molecular docking. The enriched pathways of key targets were examined by GO and KEGG.
13 components and 250 targets of RC on PCOS were screened. The core network was filtered based on topological parameters, and the key components were palmatine, berberine, berberrubine, quercetin, and epiberberine. The key targets included DRD2, SLC6A4, CDK2, DPP4, ESR1, AKT2, PGR, and AKT1. Molecular docking displayed that the active ingredients of RC had good binding activities with potential targets of PCOS. After enrichment analysis, 30 functional pathways were obtained, including neuroactive ligand-receptor interaction, dopaminergic synapse, and cAMP signaling pathway.
In summary, this study clarified the potential effect of RC on PCOS, which is helpful to provide references for clinical practice. It is also conducive to the secondary development of RC and its monomer components.
(某种药物,此处未明确给出全称,暂用RC表示)对多囊卵巢综合征(PCOS)显示出显著疗效,但其在PCOS中的作用机制仍不清楚。
通过中药系统药理学数据库与分析平台(TCMSP)检索RC的成分。通过PubChem查询活性成分的Smiles编号,并从瑞士靶点预测数据库获得预测靶点。检索药物银行(DrugBank)、基因卡片(GeneCards)和疾病基因数据库(DisGeNET)以获取PCOS的相关靶点。然后构建化合物-靶点网络。使用蛋白质-蛋白质相互作用(PPI)分析对核心靶点进行分析,并通过分子对接验证结合活性。通过基因本体论(GO)和京都基因与基因组百科全书(KEGG)检查关键靶点的富集途径。
筛选出RC对PCOS的13种成分和250个靶点。基于拓扑参数筛选核心网络,关键成分有巴马汀、小檗碱、小檗红碱、槲皮素和表小檗碱。关键靶点包括多巴胺受体D2(DRD2)、溶质载体家族6成员4(SLC6A4)、细胞周期蛋白依赖性激酶2(CDK2)、二肽基肽酶4(DPP4)、雌激素受体1(ESR1)、蛋白激酶B2(AKT2)、孕激素受体(PGR)和蛋白激酶B1(AKT1)。分子对接显示RC的活性成分与PCOS的潜在靶点具有良好的结合活性。富集分析后,获得30条功能途径,包括神经活性配体-受体相互作用、多巴胺能突触和环磷酸腺苷(cAMP)信号通路。
总之,本研究阐明了RC对PCOS的潜在作用,有助于为临床实践提供参考。也有利于RC及其单体成分的二次开发。